Purpose of reviewTo highlight recently published, clinically focused research on chronic lung disease in adult persons with human immunodeficiency virus-1 (HIV) (PWH).Recent findingsChronic lung disease was the most common comorbidity in hospitalized PWH in New York and second-most common condition in ambulatory PWH in Canada. The elevated risk of chronic obstructive pulmonary disease in PWH has been widely recognized, but PWH are also at higher risk for asthma and worse asthma outcomes. Expanded assessments of lung structure and function, such as single-breath diffusing capacity of carbon monoxide (DLCO), exhaled nitric oxide (FeNO), and chest computed tomography (CT) have provided new insights into HIV effects on the lungs. New biomarker analyses are emerging, but further studies are needed to validate predictive biomarkers for chronic lung disease in PWH. Clinical trials addressing chronic lung disease in PWH are few in number.SummaryChronic lung disease is a common and high-impact comorbidity among PWH. Future studies should collect more comprehensive lung assessments such as DLCO, FeNO, and chest CT in order to better phenotype lung derangements in HIV. Clinical trials are desperately needed to reduce the rising burden of chronic lung disease in PWH.
|Original language||English (US)|
|Number of pages||7|
|Journal||Current Opinion in HIV and AIDS|
|State||Published - May 1 2021|
Bibliographical noteFunding Information:
This material is the result of work supported with resources and the use of facilities at the Minneapolis Veterans Affairs Medical Center, Minneapolis/USA. This work was also supported by grant support Dr Kunisaki received for HIV-associated lung disease research from the National Institutes of Health (R01 HL140971, U01 HL146208, U01 HL146193).
© 2021 Lippincott Williams and Wilkins. All rights reserved.
- chronic obstructive pulmonary disease
- lung disease